bioMérieux Logo

bioMérieux

Provides in vitro diagnostic solutions for clinical and industrial microbiology.

BIM | PA

Overview

Corporate Details

ISIN(s):
FR0013280286 (+13 more)
LEI:
549300AK8Y0LBIQ4T071
Country:
France
Address:
376 CHE DE L'ORME, 69280 MARCY-L'ETOILE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

bioMérieux is a global leader in the field of in vitro diagnostics, dedicated to improving public health worldwide. Since its founding in 1963, the company has developed and provided comprehensive diagnostic solutions—including systems, reagents, software, and services—that enable critical decision-making for clinicians and industrial quality control professionals. The company's activities are focused on two primary areas: clinical diagnostics and industrial microbiology. In the clinical market, its solutions support the diagnosis of infectious diseases, management of sepsis, cardiovascular emergencies, and antimicrobial stewardship. For industrial applications, bioMérieux offers microbiological testing solutions to ensure the safety and quality of food, pharmaceutical, and cosmetic products. The portfolio features advanced systems like BIOFIRE® (multiplex PCR), VITEK® (microbial identification), and BACT/ALERT® (automated blood culture) to deliver rapid and reliable results.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-04 11:17
Declaration of Voting Results & Voting Rights Announcements
Octobre 2025 - Déclaration sur le nombre d'actions composant le capital social …
French 108.2 KB
2025-09-02 11:11
Declaration of Voting Results & Voting Rights Announcements
Août 2025 - Déclaration sur le nombre d'actions composant le capital social et …
French 106.1 KB
2025-08-05 09:41
Declaration of Voting Results & Voting Rights Announcements
Juillet 2025 - Déclaration sur le nombre d'actions composant le capital social …
French 105.8 KB
2025-06-16 07:01
M&A Activity
bioMérieux strengthens its next-generation sequencing capabilities with the acq…
English 222.9 KB
2025-06-16 07:01
M&A Activity
bioMérieux renforce ses capacités de séquençage de nouvelle génération avec l’a…
French 248.3 KB
2025-06-03 16:05
Declaration of Voting Results & Voting Rights Announcements
Mai 2025 - Déclaration sur le nombre d'actions composant le capital social et s…
French 106.1 KB
2025-06-03 07:01
Environmental & Social Information
bioMérieux launches cutting-edge equine infectious respiratory disease testing
English 276.4 KB
2025-06-03 07:01
Regulatory News Service
bioMérieux lance un test diagnostic innovant pour détecter les maladies respira…
French 274.0 KB
2025-05-05 11:37
Declaration of Voting Results & Voting Rights Announcements
Avril 2025 - Déclaration sur le nombre d'actions composant le capital social et…
French 106.1 KB
2025-04-22 07:01
Environmental & Social Information
WATCHFIRE™ by bioMérieux: a PCR test to detect viruses and bacteria in wastewat…
English 277.8 KB
2025-04-22 07:01
Regulatory News Service
WATCHFIRE™, un nouveau test PCR développé par bioMérieux pour détecter les viru…
French 267.8 KB
2025-04-17 07:01
Investor Presentation
bioMérieux – First-Quarter 2025 Business Review
English 325.6 KB
2025-04-17 07:01
Earnings Release
bioMérieux – Information financière du 1er trimestre 2025
French 281.7 KB
2025-04-07 07:01
Regulatory News Service
bioMérieux obtains CE-marking for LUMED™ APSS™, a cutting-edge software solutio…
English 276.6 KB
2025-04-07 07:01
Business and Financial Review
bioMérieux obtient le marquage CE pour LUMED™ APSS™, une solution logicielle de…
French 262.7 KB

Automate Your Workflow. Get a real-time feed of all bioMérieux filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for bioMérieux

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for bioMérieux via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-09-04 N/A Other Sell 1,432 137,517.82 EUR
2023-09-04 N/A Other Sell 1,253 120,328.10 EUR
2023-09-01 N/A Other Other 2,900 N/A
2023-06-23 N/A Other Other 323 24,971.13 EUR
2023-06-23 N/A Other Buy 323 24,971.13 EUR
2023-06-23 N/A Other Buy 300 23,193.00 EUR
2023-06-23 N/A Other Buy 25 1,932.75 EUR
2023-03-23 N/A Other Sell 16,500 1,650,415.80 EUR

Peer Companies

NanoGroup S.A. Logo
Develops patented nanotechnology for oncology and transplantology diagnostics and therapies.
Poland
NNG
NanoRepro AG Logo
Develops and distributes rapid diagnostic self-tests for early disease detection.
Germany
NN6
NANOVIRICIDES, INC. Logo
Developing biomimetic nanomachines as broad-spectrum drugs to neutralize viral infections.
United States of America
NNVC
Nasus Pharma Ltd Logo
Develops powder-based intranasal drugs for rapid delivery in acute medical emergencies.
United States of America
NSRX
NATAC Logo
Develops sustainable plant extracts for nutraceutical, pharma, food, and animal nutrition industries.
Spain
NAT
Natera, Inc. Logo
Provides non-invasive cfDNA tests for oncology, women's health, and organ health.
United States of America
NTRA
Biotech R&D of natural ingredients for health and wellness solutions.
South Korea
168330
Naturland Holding PLC Logo
A Hungarian company providing full-scale pharmaceutical manufacturing from R&D to sales.
United Kingdom
NATUR
NEKTAR THERAPEUTICS Logo
Biopharma developing innovative medicines for autoimmune and inflammatory conditions.
United States of America
NKTR
NEOGEN CORP Logo
Provides diagnostic tests and genomics services for food, animal, and agricultural safety.
United States of America
NEOG

Talk to a Data Expert

Have a question? We'll get back to you promptly.